Results 31 to 40 of about 6,312 (217)

Prospects for combining immune checkpoint blockade with PARP inhibition

open access: yesJournal of Hematology & Oncology, 2019
The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble.
Anping Li   +5 more
doaj   +1 more source

Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model

open access: yesFrontiers in Oncology, 2020
Despite the success of immune checkpoint blockade in cancer, the number of patients that benefit from this revolutionary treatment option remains low.
Evelyn Sirait-Fischer   +13 more
doaj   +1 more source

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects

open access: yesFrontiers in Oncology, 2021
Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to ...
Remy Thomas   +4 more
doaj   +1 more source

Photodynamic Therapy and Immune Checkpoint Blockade† [PDF]

open access: yesPhotochemistry and Photobiology, 2020
AbstractImmune checkpoints including PD‐1 and CTLA‐4 help to regulate the intensity and timeframe of the immune response. Since they become upregulated in cancer and prevent sufficient antitumor immunity, monoclonal antibodies against these checkpoints have shown clinical promise for a range of cancers.
Gwendolyn M. Cramer   +3 more
openaire   +2 more sources

Key questions about the checkpoint blockade-are microRNAs an answer?

open access: yesCancer Biology & Medicine, 2018
The introduction of immune-checkpoint blockade in the cancer therapy led to a paradigm change of the management of late stage cancers. There are already multiple FDA approved checkpoint inhibitors and many other agents are undergoing phase 2 and early ...
Mihnea Dragomir   +3 more
doaj   +1 more source

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade

open access: yesiScience, 2020
Summary: Interleukin-34 (IL-34) is an alternative ligand to colony-stimulating factor-1 (CSF-1) for the CSF-1 receptor that acts as a key regulator of monocyte/macrophage lineage.
Naoki Hama   +12 more
doaj   +1 more source

Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator

open access: yesActa Pharmaceutica Sinica B, 2023
The use of checkpoint-blockade antibodies is still restricted in several malignancies due to the modest efficacy, despite considerable success in anti-tumor immunotherapy.
Qingqing Xiao   +9 more
doaj   +1 more source

MCT4 blockade increases the efficacy of immune checkpoint blockade

open access: yesJournal for ImmunoTherapy of Cancer, 2023
Background & Aims Intratumoral lactate accumulation and acidosis impair T-cell function and antitumor immunity. Interestingly, expression of the lactate transporter monocarboxylate transporter (MCT) 4, but not MCT1, turned out to be prognostic for the survival of patients with rectal cancer, indicating that ...
Babl, Nathalie   +25 more
openaire   +3 more sources

Vaccination-enabled immune readiness for checkpoint blockade

open access: yesFrontiers in Immunology
Immune checkpoint blockade has transformed cancer therapy by demonstrating that durable tumour control can be achieved through immune modulation rather than direct cytotoxicity.
Jhommara Bautista   +1 more
doaj   +1 more source

Activation of phagocytosis by immune checkpoint blockade [PDF]

open access: yesFrontiers of Medicine, 2018
Inhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immune evasion. One mechanism inhibiting the innate response is the presence of the macrophage inhibitory molecule, signal regulatory protein-α (SIRPα), on tumor-associated macrophages (TAMs) and its cognate ligand cluster of differentiation 47 (CD47) on ...
Li, Chia-Wei   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy